Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P51159: Variant p.Leu130Pro

Ras-related protein Rab-27A
Gene: RAB27A
Feedback?
Variant information Variant position: help 130 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Proline (P) at position 130 (L130P, p.Leu130Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In GS2; strongly affects GTP binding; cannot interact with MLPH. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 130 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 221 The length of the canonical sequence.
Location on the sequence: help VRNWISQLQMHAYCENPDIV L CGNKSDLEDQRVVKEEEAIA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         VRNWISQLQMHAYCENPDIVLCGNKSDLEDQRVVKEEEAIA

                              VRNWISQLQMHAYCENPDIVLCGNKSDLEDQRVVKEEDARG

Mouse                         VRNWISQLQMHAYCENPDIVLCGNKSDLEDQRAVKEEEARE

Rat                           VRNWISQLQMHAYCENPDIVLCGNKSDLEDQRAVKEEEARE

Pig                           VRNWISQLQMHAYCENPDIVLCGNKSDLEDQRVVKEEEARG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 221 Ras-related protein Rab-27A
Disulfide bond 123 – 188
Beta strand 128 – 133



Literature citations
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome.
Menasche G.; Pastural E.; Feldmann J.; Certain S.; Ersoy F.; Dupuis S.; Wulffraat N.; Bianchi D.; Fischer A.; Le Deist F.; de Saint Basile G.;
Nat. Genet. 25:173-176(2000)
Cited for: VARIANTS GS2 GLY-73; PRO-130 AND PRO-152; Biochemical and functional characterization of Rab27a mutations occurring in Griscelli syndrome patients.
Menasche G.; Feldmann J.; Houdusse A.; Desaymard C.; Fischer A.; Goud B.; de Saint Basile G.;
Blood 101:2736-2742(2003)
Cited for: CHARACTERIZATION OF VARIANTS GS2 GLY-73; PRO-130 AND PRO-152; Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome.
Bahadoran P.; Busca R.; Chiaverini C.; Westbroek W.; Lambert J.; Bille K.; Valony G.; Fukuda M.; Naeyaert J.-M.; Ortonne J.-P.; Ballotti R.;
J. Biol. Chem. 278:11386-11392(2003)
Cited for: CHARACTERIZATION OF VARIANTS GS2 GLY-73; PRO-130 AND PRO-152;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.